Re-engineered, blue light-activated immune cells penetrate and kill solid tumors
HERSHEY, Pa. — Immunotherapies that mobilize a patient’s own immune system to fight cancer have become a treatment pillar. These therapies, including CAR T-cell therapy, have performed well in cancers like leukemias and lymphomas, but the results have been less promising in solid tumors.
A team led by researchers from the Penn State College of Medicine has re-engineered immune cells so that they can penetrate and kill solid tumors grown in the lab. They created a light-activated switch that controls protein function associated with cell ...










